← board
ADIA
distress 5/10 · elevated risk$0.10-1%today-57% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.8 yrs
Shares 1y
0%
Price & events
-26.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-28.3%
1W
-20.0%
1M
-45.3%
3M
-26.2%
6M
+160.0%
1Y
+642.9%
2Y
+2500.0%
5Y
+1980.0%
All
Overview
- Market Cap
- $9.82M
- Volume
- 100
- 52 Week Range
- $0.03 – $0.24
- Total Shares
- 94.40M
- Float Shares
- 72.40M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.00%
- RVOL
- 0.01x
- Beta
- -8.43
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 94,404,696 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.